Alfuzosin

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Alfuzosin
Alfuzosin.svg
Alfuzosin ball-and-stick.png
Systematic (IUPAC) name
N-[3-[(4-amino-6,7-dimethoxy-quinazolin-2-yl)- methyl-amino]propyl] tetrahydrofuran- 2-carboxamide
Clinical data
Trade names Uroxatral
AHFS/Drugs.com monograph
MedlinePlus a64002
Pregnancy cat.
Legal status
Routes Oral
Pharmacokinetic data
Bioavailability 49%
Protein binding 82%-90%
Metabolism Hepatic (CYP3A4-mediated)
Half-life 10 hours
Excretion Fecal (69%) and renal (24%)
Identifiers
CAS number 81403-80-7 YesY
ATC code G04CA01
PubChem CID 2092
DrugBank DB00346
ChemSpider 2008 YesY
UNII 90347YTW5F YesY
KEGG D07124 YesY
ChEBI CHEBI:51141 YesY
ChEMBL CHEMBL709 YesY
Chemical data
Formula C19H27N5O4 
Mol. mass 389.449 g/mol
 YesY (what is this?)  (verify)

Alfuzosin (INN, provided as the hydrochloride salt) is an α1 receptor antagonist used to treat benign prostatic hyperplasia (BPH). It works by relaxing the muscles in the prostate and bladder neck, making it easier to urinate.

Alfuzosin is marketed in the United States by Sanofi Aventis under the brand name Uroxatral and elsewhere under the tradename Xat, and in Egypt under name of Prostetrol. Alfuzosin was approved by the FDA for treatment of BPH in June 2003.

Side effects[edit]

The most common side effects are dizziness (due to postural hypotension), upper respiratory tract infection, headache, and fatigue.abdominal disturbances.

Contraindications[edit]

Alfuzosin should be used with caution in patients with severe renal insufficiency, and should not be prescribed to patients with a known history of QT prolongation who are taking medications known to prolong the QT interval.

External links[edit]